Padagis LLC
https://padagis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Padagis LLC
Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
Hyloris Announces Approval Of Condylox First Generic
Hyloris has received US approval for its generic podofilox gel, previously referred to as HY-016.
Padagis Seeks To Challenge Hikma’s Kloxxado
Padagis has set out two first-to-file ANDA submissions in the US, challenging Hikma’s Kloxxado as well as Evofem’s Phexxi. The former Perrigo Rx business has also just launched two limited-competition generics.
Padagis Achieves A US First With Budesonide Foam Launch
Padagis has launched budesonide 2mg rectal foam, the first US generic version of Uceris, with 180 days of competitive generic therapy exclusivity.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice